Lurasidone - Sumitomo Dainippon Pharma

Drug Profile

Lurasidone - Sumitomo Dainippon Pharma

Alternative Names: Latuda; Lurasidone HCl; Lurasidone hydrochloride; SM-13496; SMP-13496

Latest Information Update: 24 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Daiichi Sankyo Company; DKSH Singapore; DKSH Thailand; Standard Chemical & Pharmaceutical Company; Sumitomo Dainippon Pharma; Sunovion Pharmaceuticals; Takeda
  • Class Antipsychotics; Cyclohexanes; Isoindoles; Piperazines; Small molecules; Thiazoles
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 1A receptor agonists; Serotonin 2A receptor antagonists; Serotonin 2C receptor antagonists; Serotonin 7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Bipolar depression; Schizophrenia
  • Preregistration Bipolar disorders
  • Phase III Autistic disorder; Major depressive disorder
  • No development reported Psychiatric disorders

Most Recent Events

  • 21 Nov 2017 Sumitomo Dainippon Pharma enter into a marketing agreement with Angelini for lurasidone in the EU countries and Turkey
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Psychiatric-disorders(In adolescents, In children) in USA (PO, Tablet)
  • 30 Oct 2017 Interim efficacy and adverse events data from a phase III trial in Schizophrenia, Autism and Bipolar disorders released by Sunovion
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top